BONE GRAFTS (ORAL MAXILLOFACIAL AND DENTAL) HEALTHCARE PROFESSIONALS

INFUSE BONE GRAFT

Infuse Bone Graft

InfuseTM Bone Graft contains a manufactured bone graft material that is approved by the U.S. Food and Drug Administration (FDA) for use in certain maxillofacial bone grafting procedures, such as sinus augmentation and localized alveolar ridge augmentation. It provides an alternative to bone-harvest surgery.

Indications, Safety, and Warnings

Read More

GRAFTON DBM

Grafton Bone Graft

Grafton™ Demineralized Bone Matrix (DBM) is the most utilized and scientifically studied DBM brand.* Grafton Plugs can be placed in bone voids such as extraction sockets.

Indications, Safety, and Warnings

Read More

MASTERGRAFT GRANULES AND MINI GRANULES

HCP Osteoconduction

Mastergraft Granules and Mini Granules are synthetic, osteoconductive, resorbable scaffolds that support new bone formation while remodeling. They may be used alone or in combination with autograft to provide a bone void filler that is resorbed/remodeled and is replaced by host bone during the healing process.

Indications, Safety, and Warnings

Read More

INDICATIONS, CONTRAINDICATIONS, WARNINGS, AND PRECAUTION FOR INFUSE BONE GRAFT FOR CERTAIN ORAL MAXILLOFACIAL AND DENTAL REGENERATIVE USES 

INFUSE® Bone Graft is indicated as an alternative to autogenous bone graft for sinus augmentations, and for localized alveolar ridge augmentations for defects associated with extraction sockets.

The INFUSE® Bone Graft consists of two components–recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) placed on an absorbable collagen sponge (ACS). These components must be used as a system for the prescribed indication. The bone morphogenetic protein solution component must not be used without the carrier/scaffold component or with a carrier/scaffold component different from the one described in the package insert.

INFUSE® Bone Graft is contraindicated for consumers with a known hypersensitivity to recombinant human Bone Morphogenetic Protein-2, bovine Type I collagen or to other components of the formulation and should not be used in the vicinity of a resected or extant tumor, in consumers with any active malignancy or consumers undergoing treatment for a malignancy, in pregnant women, or consumers with an active infection at the operative site.

There are no adequate and well-controlled studies in human pregnant women. In an experimental rabbit study, rhBMP-2 has been shown to elicit antibodies that are capable of crossing the placenta. Women of childbearing potential should be warned by their surgeon of potential risk to a fetus and informed of other possible dental treatments. The safety and effectiveness of this device has not been established in nursing mothers. Women of childbearing potential should be advised to not become pregnant for one year following treatment with this device.

INFUSE® Bone Graft has not been studied in consumers who are skeletally immature (<18 years of age or no radiographic evidence of epiphyseal closure).

Please see the package insert for the complete list of indications, warnings, precautions, adverse events, clinical results, and other important medical information.

CONTRAINDICATIONS: GRAFTON DBM

The following are contraindications for the use of GRAFTON™ DBM and GRAFTON PLUS™ DBM:

  • The presence of infection at the transplantation site
  • Treatment of spinal insufficiency fractures

CAUTION: GRAFTON DBM

This allograft may contain trace amounts of antibiotics (gentamicin), surfactant, and other processing solutions. Caution should be exercised if the patient is allergic to these antibiotics or chemicals. GRAFTON PLUS™ DBM Paste contains starch. Therefore, caution should be exercised in using GRAFTON PLUS™ DBM Paste in a patient with a starch allergy and/or amylase deficiency.

For more information, see Indications, Safety, and Warnings.

CONTRAINDICATIONS: MASTERGRAFT GRANULES

This product is not intended to provide structural support during the healing process, therefore, Mastergraft Granules is contraindicated where the device is intended as structural support in the skeletal system.

Conditions representing relative contraindications include:

  • Severe neurological or vascular disease
  • Uncontrolled diabetes
  • Hypercalcemia
  • Pregnancy
  • Where stabilization of fracture is not possible
  • Segmental defects
  • Where there is significant vascular impairment proximal to the graft site
  • When there are systemic and/or metabolic disorders that affect the bone or wound healing
  • Any patient unwilling to follow postoperative instructions
  • Any case not described in the indications

POTENTIAL ADVERSE EVENTS: MASTERGRAFT GRANULES

A listing of potential adverse events includes, but is not limited to:

  • Deformity of the bone at the surgical site
  • Fracture or extrusion of the Mastergraft Granules, with or without generation of particulate debris
  • Wound complications including hematoma, site damage, infection, bone fracture, and other complications common to any surgical procedure
  • Incomplete or lack of osseous ingrowth into bone void, as possible with any bone filler

For more information, see Indications, Safety, and Warnings.


*

Based on Pub-Med search on 8/26/14 with keywords Grafton, DBX and Osteosponge.